Victoria Socha

DocwireNews

Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients with advanced renal cell carcinoma (RCC) in the phase 3 CheckMate 214 trial. The trial included treatment-na&iuml;ve patients with clear-cell, advanced RCC with International Metastatic RCC Database Consortium (IMDC) intermediate/poor risk.During a poster session at the ASCO 2019 Annual Meeting, David F. McDermott, MD<a href="https://www.bidmc.org/">,</a> and colleagues reported results of a post-hoc exploratory analyses of nivolumab plus ipilimumab versus sunitinib in CheckMate 214 RCC patients with sarcomatoid features (sRCC). To identify the presence of sarcomatoid features, the researchers performed a keyword search for sarcomatoid in patients with available pathology reports accompanying pretreatment tumor samples. Results of the analysis were reported in a poster titled CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features.Of 1096<a href="https://www.docwirenews.com/latest-nephrology-news/keynote-427-updated-results-from-cohort-a/"> intention-to-treat</a> patients, 77% (n=842) had local pathology reports available, including 112 randomized patients with intermediate/poor risk scores (N plus I, n=60; S, n=52). Baseline characteristics of sRCC patients were balanced between the two arms. At baseline, 47% of intermediate/poor risk sRCC patients in the nivolumab plus ipilimumab arm and 53% of intermediate/poor risk sRCC patients in the sunitinib arm had tumor PD-L1 expression &ge;1%, compared with 26% and 29% of all intermediate/poor risk patients, respectively.Descriptive analyses were performed at a minimum follow-up of 30 months. Results confirmed that nivolumab plus ipilimumab improved overall response rate and complete response rate per investigator (Response Evaluation Criteria in Solid Tumors, version 1.1), overall survival, and progression-free survival per investigator compared with sunitinib in intermediate/poor risk patients with sRCC. There were no new safety signals seen in sRCC patients.In conclusion, the researchers said, &ldquo;In this post hoc descriptive subgroup analysis of CheckMate 214, nivolumab plus ipilimumab demonstrated promising efficacy and prolonged survival versus sunitinib, with consistent safety, in previously untreated intermediate/poor risk, advanced clear-cell RCC with sarcomatoid features. Prospective studies of nivolumab plus ipilimumab that include patients with sRCC are ongoing.&rdquo;Clinical trial information: NCT02231749Source: McDermott DF, Choueiri TK, Motzer R. et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

Hatem Soliman, MD

Neoadjuvant Immunity: Oncolytic Virus + Chemo Shows Promise in Early TNBC

Triple-Negative Breast Cancer

Leah Lawrence

Epilepsy Prevalence Increased Years Before Frontotemporal Dementia Diagnosis

Epilepsy

Selenium Compound Shields Against Ulcerative Colitis

Gastroenterology

Latest News

Nivolumab plus Ipilimumab versus Sunitinib

ASCO 2019

Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients with advanced renal cell carcinoma (RCC) in the phase 3 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe